SANTÉ

At Santé, our priority is partnering with firms who consistently create innovative solutions for improving patient care. A great example of this is FARAPULSE, Inc., which was acquired by Boston Scientific in 2021.   The company’s Pulsed-Field Ablation (PFA) system went to market in February of this year, and as noted below in Medical Device Network, physicians are already showing a strong preference for the Farapulse PFA, compared to other options. It’s this commitment to creating products that best meet patient needs, while in many cases also reducing the financial burden of care, that sets the companies in our network apart.   #venturecapital #healthcare #pfa #FDAapproval   https://lnkd.in/eeMdx9J2

With more than 6.7 million Americans suffering from heart failure today, the need for innovative treatment is clear.   That’s why we are excited to be a co-lead on Reprieve Cardiovascular's $42M Series A round! The company has created a ground-breaking approach to monitoring physiological parameters when delivering personalized diuretic dosing and fluid replacement for patients with ADHF (Acute Decompensated Heart Failure). The financing will be used to further advance Reprieve’s clinical and development programs, including the ongoing FASTR trial and its upcoming pivotal trial.   More details in the link below!   #venturecapital #healthcare #ADHF   https://lnkd.in/ej-782mq

We're proud to work with companies who are making incredible strides to improve patient care. One of them is Geneos Therapeutics, who just announced the results of their most recent preliminary study, which found that one-third of patients with advanced liver cancer saw their tumors shrink after receiving the company’s personalized vaccine.   While they still need to be confirmed in a larger trial, the result was roughly twice the response typically seen with the immunotherapy alone. It’s a big step forward in the development of effective cancer vaccines, which ultimately will be crucial in treating a disease that continues to claim millions of lives.   Congrats to the full Geneos team!   https://lnkd.in/e3caxm8j

Attending LSI next week? If so, be sure to join Dennis McWilliams who will be moderating a panel on Wednesday March 20th covering the importance of venture capital fund size.   This is an important topic for Sante and one we have issued quite a bit of research on. As we’ve noted before, larger funds do not necessarily translate to higher exit values.   The panel is titled “Does Venture Scale? Fund Size Logic, Considerations, and Misconceptions” and joining Dennis for the discussion will be Amir Soltanianzadeh, Owen Willis, Nancy Hong, and Thom Rasche.   More details in this year’s agenda below!   https://lnkd.in/dg6MQXuq

Big news from Endogenex - the company announced IDE approval this week for a pivotal clinical study of their ReCET System. ReCET is designed to help adults with Type 2 diabetes whose treatments are inadequately controlled by non-insulin, glucose lowering medications. It's another great achievement for a SANTÉ portfolio company, seeking a new and innovative approach to improving care. https://lnkd.in/eEvzkvnj

Proud of our portfolio company,  Reimagine Care, for delivering at-home cancer care at scale in 2023 and for redefining how cancer care can delivered with the patient at the center of care

Congratulations to Endovascular Engineering on receiving IDE approval to start the ENGULF Pivotal trial!   Endovascular Engineering (E2) focuses on the development and deployment of groundbreaking clot removal technologies that target venous thromboembolism (VTE). Today they received Investigational Device Exemption (IDE) from the FDA to begin the ENGULF pivotal trial in the US. This will allow the company to evaluate the safety and effectiveness of its Hēlo Thrombectomy System in treating pulmonary embolism (PE) - marking a significant step forward in the development of innovative clot removal technologies.   E2 is part of our third fund and we were a co-lead in the Series A funding round.   More details in the press release below!   https://lnkd.in/eAUyqQkm

Congrats to BeeKeeperAI on the announcement of your new product upgrade! This is a great example of advancing AI’s integration into healthcare, and improving the patient experience. Proud to be a partner in your effort to enhance data privacy and empower risk free data sharing. https://lnkd.in/eWubJTyy

When SANTÉ was founded nearly two decades ago, we committed to something we think is critical in venture capital, yet often underappreciated – the importance of maintaining a disciplined fund size.   This year, we issued the third iteration of research detailing just how important fund size is for performance – regardless of the market environment you operate in. Our updated research reconfirmed that there are distinct limitations to what a venture fund can return, which do not scale with size. It’s imperative to realize that each investment has to have the potential to return a substantial fraction of the entire fund, without relying on unicorn exits.   Proud to issue our latest research on this, detailed in the link below.   https://lnkd.in/gaFs_jqm

Congrats to ABK Biomedical Inc. Biomedical on this announcement! The FDA has granted Breakthrough Device Designation for the company’s Eye90 microspheres solution.   This treatment hopes to significantly improve outcomes for patients living with unresectable Hepatocellular Carcinoma (HCC) – one of the most common types of liver cancer.   https://lnkd.in/dHf3GsKy